0.09 (1.05%) 1d

Related posts

TSX flat while Wall Street ralliesStocks and cryptos modestly climbStocks sink ahead of tech earnings and Fed
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

The reviews for Bausch Health Companies Inc (BHC-N) are quite negative, with one expert stating that they are stunned by how poorly it's done. This suggests that the company may be facing significant issues or challenges. Investors should approach with caution and conduct thorough research before considering any investments in this company.

Vale, VALE3.SA

Is stunned by how poorly it's done.

He suspect the shares are being manipulated down. There's no reason that the shares should be this low, down 61% in the last three months. But he's hanging on.
He bought it today. It's a comeback story. This used to be the hated, shady, debt-heavy Valeant which collapsed in 2015. Then, the new CEO did a remarkable job settling its legal problems, repaying a lot of debt, fixing the business model and stabilizing the business. Last year, the CEO planned to spin off Bausch and Lomb as its own eyecare business and Solta, the asthetic business by early 2022. Solta had $219 million in sales through the first 9 months of 2021. Solta products gives people smooth skin. This business grows at 27%, and should generate $171.5 million in EBITDA. What's left after the spin-offs is a pure-play pharma business. But Bausch still carries a mountain of debt. All told, he sees much more upside.
Has been rangebound for two years, but recently broke out. That's good--it's going higher. Support around $36 and he predicts it will fall back here during the predicted market pullback to come.
The former Valient Pharmaceuticals. It looks like it could rally $10 on a new breakout. Hold off until for a while as he does not see a real trend forming yet. Trade with a $28 stop-loss. (Analysts’ price target is $40.00)
There is no yield, so it falls outside his ranking system. Overall growth in earnings is basically flat. The PE ratio is only 5 times so he feels the market is somewhat skeptical.
R&D-to-sales metric steered him away from Valeant (what Bausch used to be named). The current CEO is doing a great job transitioning and paying debt and de-risking the company. They appear to be doing well during this restructuring.

You have been through ups and down with this one including a name change from Valiant. It has decent price momentum. They are trying to reconcile their balance sheet. Forward numbers look a lot better than backward looking numbers. They are not cheap enough and it is still a volatile stock. They have too much debt so avoid it.


Formally Valiant. It had a rise and fall from grace. It bottomed over the last year. There is a lot of volatility. They addressed some of the concerns. Investors worry about R&D; and about drugs coming off patent. He does not know about their pipelines. If you can handle the risk, there are few companies where you can play the sector. There are more names in the US in this space that are attractive.

Showing 1 to 9 of 9 entries
  • «
  • 1
  • »

Bausch Health Companies Inc(BHC-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Bausch Health Companies Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bausch Health Companies Inc(BHC-N) Frequently Asked Questions

What is Bausch Health Companies Inc stock symbol?

Bausch Health Companies Inc is a American stock, trading under the symbol BHC-N on the New York Stock Exchange (BHC). It is usually referred to as NYSE:BHC or BHC-N

Is Bausch Health Companies Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about BHC-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bausch Health Companies Inc.

Is Bausch Health Companies Inc a good investment or a top pick?

Bausch Health Companies Inc was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Bausch Health Companies Inc.

Why is Bausch Health Companies Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bausch Health Companies Inc worth watching?

1 stock analyst on Stockchase covered Bausch Health Companies Inc In the last year. It is a trending stock that is worth watching.

What is Bausch Health Companies Inc stock price?

On 2024-04-19, Bausch Health Companies Inc (BHC-N) stock closed at a price of $8.69.